COVID-19 Testing

Our comprehensive patient-centric solution

includes three tests

SDI Labs’ Covid-19 Testing For Quality Patient Care

Our viral RT-PCR test test was authorized under FDA (EUA)

Viral RT-PCR RNA Test

Our viral RT-PCR RNA test was authorized under FDA (EUA) in late March and is 99.9% accurate. Our Viral RT-PCR RNA test is used as the first diagnostic method to determine if an active COVID-19 infectious is present in the patient

  • Our viral RT-PCR test was authorized under FDA (EUA) with a proven accuracy rate of 99.9% to diagnose an active COVID-19 infection

  • SDI uses an automated process to return results within 24-72 hours

  • Our test is made in the USA and SDI Labs is licensed to test in all 50 states

Antigen (Rapid Diagnostic) Testing

Antigen testing also referred to as rapid testing, is used to detect active infection. However, antigen testing is less accurate than RT-PCR. It can be used under clinical supervision and with the observation of symptoms to evaluate results.

  • Antigen results may be obtained in less than 15 minutes at the point of care

  • SDI Labs Antigen Kit can be collected with a nasopharyngeal or an anterior nasal swab

  • Coming soon! (Currently awaiting final EUA authorization)

RT-PCR RNA vs Antibody

A COVID-19 test detects an active SARS-CoV-2 virus. An antibody test detects if an individual has had the virus in the past.

There is currently not enough evidence to support the idea that having antibodies guarantees a patient is protected against reinfection with COVID-19.

Better Together

Combining viral RT-PCR RNA tests and antibody tests allows patients to identify both if they are currently infected with COVID-19, and if they may have previously been infected.

With this information, patients have a better understanding of their health history. Meanwhile, employers are able to understand who is currently infected, who has been infected and who has not been. Based on that data, they’re able to make informed decisions about safe societal re-entry.